Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Digestive Diseases and Sciences|June 5, 2008
Whipple's disease-generalized stagePeter Jackuliak, Tomas Koller, Lahim Baqi, et al.
Canadian Journal of Gastroenterology & Hepatology|June 7, 2021
Frailty in Nonalcoholic Fatty Liver Cirrhosis: A Comparison with Alcoholic Cirrhosis, Risk Patterns, and Impact on PrognosisLubomir Skladany, Pavol Molcan, Jana Vnencakova, et al.
World Journal of Clinical Cases|June 18, 2021
Liver injury associated with the use of selective androgen receptor modulators and post-cycle therapy: Two case reports and literature reviewTomas Koller, Petra Vrbova, Iveta Meciarova, et al.
World Journal of Gastroenterology|June 28, 2017
Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational studyTomas Koller, Martina Galambosova, Simona Filakovska, et al.
United European Gastroenterology Journal|July 20, 2024
Assessment of intestinal inflammation via fecal calprotectin for early prediction of adverse outcomes in advanced chronic liver diseaseTomas Koller, Petra Vrbova, Natalia Kubanek, et al.
Bratislavske Lekarske Listy|May 23, 2023
Predictive value of infliximab trough levels in maintenance therapy for 5-year sustained clinical remission in patients with inflammatory bowel diseaseYashar Jalali, Anna Gojdicova, Igor Sturdik, et al.
European Journal of Gastroenterology & Hepatology|October 25, 2017
Decrease of trabecular bone score reflects severity of Crohn's disease: results of a case-control studyAnna Krajcovicova, Martin Kuzma, Tibor Hlavaty, et al.
Journal of Crohn'S & Colitis|September 2, 2014
Combination therapy with an immunomodulator and anti-TNFα agent improves bone mineral density in IBD patientsAnna Krajcovicova, Tibor Hlavaty, Zdenko Killinger, et al.
Journal of Clinical Medicine|October 2, 2020
Irisin in Liver CirrhosisMichał Kukla, Lubomir Skladany, Tomasz Menżyk, et al.
The EPMA Journal|March 8, 2021
Challenging management of severe chronic disorders in acute pandemic situation: Chronic liver disease under COVID-19 pandemic as the proof-of-principle model to orchestrate the measures in 3PM contextLubomir Skladany, Tomas Koller, Svetlana Adamcova Selcanova, et al.
Pageof 3